Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

REST - Replacing Steroids in the Transplant Ineligble

NCT04939844

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Zealand University Hospital Roskilde, Denmark
  • Oslo University Hospital Oslo, Norway
  • Helse Stavanger HF Stavanger, Norway
  • St. Olav University Hospital Trondheim, Norway
View Trial Details
Completed

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

NCT03397706

Conditions
Epstein-Barr Virus-Associated Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +3 more
Locations
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • UC Irvine Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of Colorado Anschutz Cancer Pavilion Aurora, Colorado, United States
View all 28 locations
View Trial Details
Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05227144

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • James R. Berenson, MD, Inc. West Hollywood, California, United States
  • Northside Hospital Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinical Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790

Conditions
Acute Myeloid Leukemia (AML), Blood Protein Disorders, Bone Marrow Diseases, +33 more
Locations
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • Oncology Institute of Hope and Innovation Pasadena, California, United States
  • Rocky Mountain Regional VA Medical Center Aurora, Colorado, United States
  • Sarah Cannon Cancer Center - (Colorado Blood Cancer Institute) Denver, Colorado, United States
View all 46 locations
View Trial Details
Completed

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

NCT05225584

Conditions
Cutaneous T-cell Lymphoma (CTCL), Hematologic Diseases, Hemic and Lymphatic Diseases, +22 more
Locations
  • UC Irvine Health-Chao Family Comprehensive Cancer Center Orange, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Henry Ford Hospital Detroit, Michigan, United States
  • Hackensack University Medical Center, John Theurer Cancer Center Hackensack, New Jersey, United States
View all 13 locations
View Trial Details

Related conditions